Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 20, 2013

Primary Completion Date

June 3, 2025

Study Completion Date

June 3, 2030

Conditions

Recurrent Hodgkin LymphomaRecurrent Non-Hodgkin LymphomaRefractory Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma

Interventions

DRUG

Brentuximab Vedotin

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors

lead

University of Washington

OTHER